Research Article

Identification of Serum Metabolomics Characteristics in Patients with Stable Angina Pectoris Using UHPLC-QE-MS

Yufei Zhou,1,2 Chen Zhou,1,2 Gang Luo,1,2 Wei Ren,2,3 Li Dong,1,2 Junjie Liang,1,2 Linshen Mao,2,3 Mengnan Liu,1,4 Yanli Dong,1,2 Pan Liang,2,3 and Sijin Yang1,2

1National Traditional Chinese Medicine Clinical Research Base and Cardiovascular Medicine Department of the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000 Sichuan, China
2College of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou, 646000 Sichuan, China
3National Traditional Chinese Medicine Clinical Research Base and Drug Research Center of the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000 Sichuan, China
4Faculty of Chinese Medicine and State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macao, 999078, China

Correspondence should be addressed to Sijin Yang; ysjimn@swmu.edu.cn

Received 28 March 2022; Accepted 21 April 2022; Published 16 May 2022

Abstract. Stable angina pectoris (SAP) is one of the main types of coronary heart disease (CHD). To improve treatment outcomes, more effective biomarkers are needed. Currently, studies on the metabolic characteristics of SAP are lacking. Here, we explored the serum metabolomic profile of SAP and identified potential biomarkers and related pathways to assist the clinical diagnosis and treatment of SAP.

Method. Thirty patients with SAP patients and 30 healthy controls (CON) without stenosis were selected for this study. All patients underwent coronary angiography. The metabolites of the two groups’ serum samples were investigated using UHPLC-QE-MS. Changes in serum metabolic profile were evaluated using multivariate statistical analysis and pathway analysis.

Result. OPLS-DA analysis identified significant differences in the serum metabolic profiles between patients with SAP and CON. Twenty-five differential metabolites were identified between patients from SAP and CON groups, including choline, creatine, L-arginine, beta-guanidinopropionic acid, isopalmitic acid, xanthine, LysoPC (18 : 1), and LysoPC (20 : 3). Pathway analysis found that these differential metabolites were involved in energy metabolism, oxidative stress, purine metabolism, and other metabolic pathways.

Conclusion. By comparing the serum metabolic profiles of SAP patients with a control group, we identified 25 potential biomarkers that could improve the clinical diagnosis and treatment of SAP.

1. Introduction

Ischemic heart disease is among the most common and most lethal causes of heart failure [1]. According to the Global Cardiovascular Burden Report statistics, 197 million patients were diagnosed with ischemic cardiomyopathy worldwide in 2019, and the burden of ischemic heart disease is increasing annually [2]. Coronary heart disease (CHD) is associated with a severe burden on the global population’s health and economy, and its age of onset is gradually getting younger ([3].

At present, coronary angiography is the gold standard for diagnosing CHD, but many patients are reluctant to undergo this examination due to its invasiveness [4]. Therefore, more research on the prevention, early diagnosis, and treatment of CHD are needed. The discovery of new biomarkers has been an important research focus to achieve this.

Technical advances have allowed researchers to use techniques such as genomics, proteomics, and metabolomics to efficiently characterize individuals of a particular disease.
Metabolomics is an approach that examines low-molecular weight metabolites (<1,000 Da) of an intact tissue or biofluid in a patient [5, 6] and has been used in patients with CHD [7–9]. The three general metabolomics technologies are nuclear magnetic resonance spectroscopy, gas chromatography–mass spectrometry, and liquid chromatography–mass spectrometry. Their use has brought new opportunities for the study of biomarkers in CHD, such as lysophosphatidylethanolamine, monoglyceride [10], docosapentadilute acid [11], unsaturated fatty acid [12], phenylacetylglutamine [13], and amino acid [14]. However, there are few metabonomic markers that can be used in the clinical diagnosis of CHD. The existing ones have the following disadvantages. First, there were several inconsistencies in the metabonomic methodologies used and pretreatment sample loading used in each study, and the detection ability of metabolites has been shown to vary with different instruments and methods. Second, many predictive biomarkers found in current research are difficult to be clinically validated due to challenges for obtaining endogenous metabolite standards. Thus, despite current advances, more studies with standard methodologies should be performed and validated to assist in the diagnosis and treatment of CHD.

In this study, we used UHPLC-QE-MS technology to detect the serum metabolomics of patients with stable angina pectoris (SAP) to identify potential biomarkers that could guide the diagnosis and treatment of SAP.

2. Materials and Methods

2.1. Patients and Study Criteria. From March 2021 to September 2021, a total of 60 participants who were treated at the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University (Sichuan, China) were enrolled. Patients with SAP diagnosed by coronary angiography were arranged into the SAP group, while those with no stenosis confirmed by coronary angiography were selected as the control group (CON). The diagnostic criteria of SAP was performed in accordance with Nomenclature and Criteria for Diagnosis of Ischemic Heart Disease, issued by Joint International Society and Federation of Cardiology/World Health Organization in 1979.

The study inclusion criteria were as follows: (1) patients aged from 40 to 80 years; (2) previous coronary angiography showed that at least one coronary artery met the following conditions: 50% ≤ main coronary artery stenosis <75% or 50% ≤ branch coronary artery stenosis <100%; and (3) patients that were to be in the CON group had to have matched basic information in terms of gender, culture, and education with those from the SAP group. The patients were excluded if they had (1) chest pain caused by neurosis, climacteric syndrome, cerebral spondylosis, gastric, esophageal reflux, unstable angina pectoris, myocardial infarction, cardiomyopathy, and other diseases; (2) myocardial infarction (at least three months before enrollment) and preinfarction symptoms several months before the study; (3) severe heart failure and malignant arrhythmia affecting hemodynamics; (4) other severe systemic diseases such as AIDS, malignancy, gastrointestinal bleeding, gastric ulcer, and bleeding tendency; (5) liver and kidney dysfunction caused by noncardiac causes; (6) valvular heart disease, congenital heart disease, and active myocarditis without operation; (7) planned pregnancy, were pregnant, or lactating; (8) a history of primary organ (i.e., lung, liver, heart, bone marrow, kidney) transplantation; (9) psychological problems; and (10) participated in other clinical researchers in the recent two months.

All patients and their families gave informed and signed consent for the anonymous use of their data. This study was approved by the ethics committee of the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University (No. KY20210008-FS01).

2.2. Sample Collection. After fasting, 5 mL of venous blood was collected between 7:00 and 8:00 am, placed in 25°C for 30 min, and centrifuged at 3000 rpm for 10 min, and then, 500 μL of the supernatant was transferred to a cryopreservation tube. After liquid nitrogen quick freezing, it was stored in a refrigerator at −80°C until measurement and experimenting purposes.

2.3. Sample Preparation. First, 50 μL of the sample was placed into an EP tube, to which 150 μL extract (100% methanol, containing iso-labeled internal standards mixture) was added, vortexed for 30 s, sonicated for 10 min (ice water bath), and incubated for 1 h at −40°C. Second, the sample was centrifuged at 12,000 rpm for 15 min at 4°C, after which the supernatant was taken to a fresh glass vial for analysis. The quality control (QC) sample was prepared by mixing an equal aliquot of the supernatants from all samples.

2.4. Metabolomics Study. The reference of the experiment method is “Optimization and Testing of Mass Spectral Library Search Algorithms for Compound Identification” [15]. UHPLC-QE-MS analyses were performed using the UHPLC system (Vanquish, Thermo Fisher Scientific) coupled to Q Exactive HFX mass spectrometer (Orbitrap MS, Thermo). Chromatographic analysis was performed using an UPLC HSS T3 (2.1 mm × 100 mm, 1.8 μm). The mobile phase consisted of 5 mmol/L of ammonium acetate and 5 mmol/L of acetic acid in water (A) and acetonitrile (B). The analysis was carried with elution gradient using the following steps: 0.7 min, 1% B; 0.7-9.5 min, 1%-99% B; 9.5-11.8 min, 99% B; 11.8-12.0 min, 99%-1% B; and 12-14.8 min, 1% B. The column temperature was kept at 35°C. The autosampler temperature was 4°C, and the injection volume was 3 μL.

All spectra data were acquired using the information-dependent acquisition (IDA) mode by control software (Xcalibur, Thermo, ver: 4.0.27). In the IDA mode, the acquisition software continuously evaluated the full scan MS spectrum. The ESI source conditions were set as follows: sheath gas flow rate as 30 Arb, Aux gas flow rate as 10 Arb, capillary temperature 350°C, full MS resolution as 60000, MS/MS resolution as 7500, collision energy as 10/30/60 in NCE mode, and spray voltage as 4.0 kV (positive) or -3.8 kV (negative), respectively.

To monitor the stability of the UHPLC-QE-MS system, all serum samples were randomized. At the beginning of the sample sequence, two blank samples and one QC sample
2. Statistical Analysis and Data Processing. After the raw data was obtained by the Xcalibur software, they were converted to the mzXML format using ProteoWizard and processed with an in-house program developed using R and based on XCMS for peak discrimination, filtering, alignment, integration, and identification. Then, an Excel file of the preprocessed data was imported into the Simca-p (ver: 16.0.2) software for OPLS-DA analysis, an effective multivariate statistical method that emphasizes global law. It focuses on ignoring the intragroup error and eliminating irrelevant random errors, which maximized the differences among groups in the model. Thus, different metabolites could be identified from the massive data obtained. On the chart, each point referred to a sample and the location of the sample depends on the difference between the metabolites it contains. From the OPLS-DA chart, the degree of aggregation and dispersion of the sample could be assessed. A more aggregated degree referred to the presence of more similar metabolite contents and components in the sample. If it was more dispersed, this referred to a greater difference of metabolite contents and components between different samples. Then, Human Metabolome Database (HMDB) and Metlin were used for metabolites identification, and an in-house MS2 database (BiotreeDB) was used for metabolite annotation. The cutoff for annotation was set at 0.3.

Potential biomarkers were screened according to relevant conditions and were analyzed using hierarchical cluster analysis and correlation analysis. Correlation analysis was used to reveal the synergy between the changes of different metabolites. If the changing trend of certain metabolites was the same, it demonstrated a positive correlation. In contrast, if it was negatively correlated, the degree of correlation between the two variables was expressed by correlation coefficient \( r \), with an \( r \) value between -1 and 1. It could be any value in this range. Positive correlation referred to an \( r \) value between 0 and 1 and a negative correlation for an \( r \) value between -1 and 0. The closer the absolute value of \( R \) to 1 referred to a stronger correlation between the two variables, and a closer absolute value of \( R \) to 0 represented a weaker correlation between two metabolites.

SPSS software (Statistical Product and Service Solutions, IBM, America, ver: 25.0) was used to test the significance level between the CON and SAP groups; \( P < 0.05 \) was considered significant.

### 3. Results

#### 3.1. Participants Characteristic. In all, 60 patients were eligible for this study, comprising of 30 patients in each group. \( t \)-tests were used to analyze the data and make comparisons between the 2 groups. There was no statistical difference in terms of sex, age, and laboratory data between the SAP and CON groups (\( P > 0.05 \)). Use of SPSS software. Their demographic and clinical characteristics are illustrated in Table 1.

#### 3.2. System Stability. The detection stability was judged by the difference in the peak height of the isotope-labeled internal standard mixture response between the QC samples. As shown in Figure 1, the retention time and response strength of the internal standard in QC samples were injected to confirm that the baseline was stable, and then, QC samples were injected once every ten sample injections.
were stable. We also observed that the instrument data acquisition stability was good.

3.3. Differences between the Metabolic Profiles of Patients with Stable Angina Pectoris and Control Subjects. A total of 7124 peaks and 1640 metabolites remained after preprocessing (deviation filtering, missing value filtering, missing value imputation, and data normalization) in both positive and negative modes. Then, the data containing the information of peak number, sample name, and normalized peak area were exported to the SIMCA software package (Sartorius Stedim Data Analytics AB, Umeå, Sweden, ver: 16.0.2) for multivariate analysis. The principle component analysis (PCA) demonstrated no significant differences between the SAP and CON groups.

To further compare the difference in serum metabolic profile between the SAP and CON groups, we used orthogonal projections to latent structure-discriminant analysis (OPLS-DA) to analyze the data. The results showed that the difference between the two groups was noticeable (Figure 2).
(1) In multivariate analysis, significant projection values greater than 1 (VIP > 1) were used as criteria for differential metabolites. (2) Paired t-test was used to compare the relative amount (peak area) of identified metabolites between the two groups ($P < 0.05$) in univariate statistical analysis. The candidate metabolites with VIP > 1 and $P < 0.05$ were considered as differential metabolites between the two groups. Based on the above conditions, a total of 89 significant metabolites were identified through the Human Metabolome Database (HMDB) and Metlin and are presented as filtered results using volcano plot (Figure 3). For a condition of MS2 score $> 0.8$, 26 differential metabolites were identified as potential biomarkers for SAP. Table 2 summarizes the detailed information of potential biomarkers.

To better understand the metabolic differences and characterize the metabolites changes between the SAP and CON

**Figure 3:** Volcano plot: each dot in the volcano map represents a metabolite containing all the substances measured in this study. (a) The abscissa represents the multiple changes of the group compared to each substance (the logarithm based on 2), and the ordinate represents the $P$ value of the Student’s $t$-test (the negative logarithm based on 10). (b) The size of dots represents the VIP value of OPLS-DA model (the larger the dot, the larger the VIP value; upregulated metabolites in red, downregulated metabolites in blue, and nonsignificant metabolites in gray).
Table 2: Potential biomarkers in stable angina pectoris based on UHPLC-QE-MS analysis in serum.

| Mode       | Metabolites                             | HMDB      | RT      | m/z   | VIP   | SAP vs. CON | P value | FC    | MS2 score | Trend |
|------------|-----------------------------------------|-----------|---------|-------|-------|-------------|---------|-------|-----------|-------|
| ESI (+)    | Phosphoric acid                         | HMDB0002142 | 529.91  | 98.98 | 3.68  | 0.00        | 0.87    | 1.00  | ↓         |
|            | Choline                                 | HMDB0000097 | 556.11  | 104.11| 3.20  | 0.01        | 0.88    | 1.00  | ↓         |
|            | Creatine                                | HMDB0000064 | 47.43   | 132.08| 1.42  | 0.03        | 0.73    | 0.99  | ↓         |
|            | Phosphorylcholine                        | HMDB0001565 | 542.14  | 184.07| 1.51  | 0.01        | 0.89    | 0.99  | ↓         |
|            | 11-beta-Hydroxyandrostereone-3-glucuronide | HMDB0010351 | 520.70  | 483.25| 1.35  | 0.04        | 0.86    | 0.93  | ↓         |
|            | LysoPC(20:3)                             | HMDB0010393 | 519.98  | 546.34| 2.48  | 0.01        | 0.82    | 0.93  | ↓         |
|            | LysoPC (18:0)                           | HMDB0010384 | 606.29  | 524.37| 3.78  | 0.00        | 0.81    | 0.92  | ↓         |
|            | Sphingosine 1-phosphate                  | HMDB0000277 | 783.51  | 380.26| 1.86  | 0.03        | 0.93    | 0.90  | ↓         |
|            | Glycoursodeoxycholic acid                | HMDB0000708 | 338.83  | 450.31| 2.28  | 0.00        | 1.16    | 0.89  | ↑         |
|            | LysoPC (22:4)                           | HMDB0010401 | 561.28  | 572.37| 2.61  | 0.01        | 0.76    | 0.88  | ↓         |
|            | LysoPC (16:0)                           | HMDB0010382 | 540.32  | 496.34| 3.87  | 0.00        | 0.84    | 0.88  | ↓         |
|            | LysoPC (P-18 : 1(9Z))                   | HMDB0010408 | 606.34  | 506.36| 3.47  | 0.00        | 0.78    | 0.84  | ↓         |
|            | LysoPC (20:2)                           | HMDB0010392 | 560.39  | 548.37| 2.63  | 0.04        | 0.87    | 0.84  | ↓         |
|            | Beta-guanidinopropionic acid             | HMDB0013222 | 65.55   | 132.08| 1.51  | 0.01        | 0.74    | 0.83  | ↓         |
|            | LysoPE (0:0/18:0)                       | HMDB0011129 | 595.80  | 482.32| 2.99  | 0.04        | 0.86    | 0.82  | ↓         |
|            | Isopalmitic acid                        | HMDB0031068 | 540.76  | 255.23| 2.46  | 0.01        | 0.85    | 1.00  | ↓         |
|            | Pyruvic acid                            | HMDB0000243 | 778.32  | 87.01 | 1.87  | 0.01        | 0.88    | 1.00  | ↓         |
|            | FA (20:3)                               | HMDB0060039 | 655.13  | 305.25| 1.18  | 0.04        | 1.21    | 1.00  | ↑         |
|            | 16-Methylheptadecanoic acid              | HMDB0031066 | 606.68  | 283.26| 3.14  | 0.00        | 0.84    | 1.00  | ↑         |
|            | Xanthine                                | HMDB0000292 | 95.84   | 151.03| 1.54  | 0.02        | 0.83    | 0.94  | ↓         |
| ESI (-)    | Epsilon-(gamma-glutamyl)-lysine         | HMDB0000386 | 452.61  | 274.14| 1.83  | 0.04        | 0.63    | 0.93  | ↓         |
|            | L-Arginine                              | HMDB00000517 | 47.21  | 173.10| 1.49  | 0.03        | 1.27    | 0.92  | ↑         |
|            | LysoPA (18 : 2)                         | HMDB0007856 | 519.75  | 433.24| 3.22  | 0.00        | 0.78    | 0.87  | ↓         |
|            | LysoPA (16 : 0)                         | HMDB0007853 | 540.77  | 409.24| 3.11  | 0.00        | 0.84    | 0.87  | ↓         |
|            | LysoPC (18 : 1)                         | HMDB0002815 | 544.41  | 580.36| 2.24  | 0.01        | 0.85    | 0.86  | ↓         |
|            | LysoPC (16 : 0)                         | HMDB0010382 | 528.80  | 554.35| 3.30  | 0.00        | 0.80    | 0.86  | ↓         |
groups, potential biomarker data were analyzed through hierarchical clustering analysis (Figure 4(a)) and correlation analysis (Figure 4(b)). In the clustering heatmap, increasing expression values are coded with blue to red colors. We observed that 3 metabolites were increased and 23 were decreased in the SAP group. Glycoursodeoxycholic acid, FA (20:3), and L-arginine were increased, while choline, sphingosine 1-phosphate, beta-guanidinopropionic acid, xanthine, LysoPC (18:0), LysoPC (22:4), and others were decreased in the SAP group.

3.4. Metabolic Pathway Analysis. Metaboanalyst 5.0 was used to investigate the metabolic pathways of the potential biomarkers. The results observed disorder in the glycine, serine, and threonine metabolism, arginine and proline metabolism, D-Arginine and D-ornithine metabolism, sphingolipid metabolism, glycerophospholipid metabolism, aminoacyl-tRNA biosynthesis, and purine metabolism in SAP group. A summary of the pathway analysis is shown in Figure 5.

4. Discussion

Our study identified 25 potential biomarkers that were associated with oxidative stress, glucose metabolism, fatty acid metabolism, and amino acid metabolism in the serum of SAP patients. Compared with the CON group, a decreasing trend in isopalmatic acid (IPA), which belong to the monomethyl branched-chain fatty acid (BCFAs) [16], in the SAP group was observed. It was reported that IPA could stimulate peroxisome proliferator-activated receptor alpha (PPAR-α) [17]. The activation of PPAR can inhibit the expression of some critical genes, such as nuclear factor kappa B, to regulate and promote inflammation in the vasculature and participate in lipid-lowering and atherosclerosis protection to reduce the risk of cardiovascular disease [18–21]. Thus, lower levels of IPA in the serum of the SAP group could relate to higher levels of inflammation in these patients [22].

Glycosyldeoxycholic acid (GUDCA) is considered to have antiapoptotic, antioxidant, and anti-inflammatory properties [23]. It has been found that GUDCA could reduce the production of lactate dehydrogenase, TNF-α, and IL-1β in the nervous system and reduce the production of cytochrome C peroxidase in neurodegenerative models [24, 25]. Other studies have found that GUDCA could reduce the development of atherosclerosis, which could be related to GUDCA downregulating the expression of scavenger receptor A1 mRNA, reducing the uptake of oxidized low-density lipoprotein, and inhibiting the formation of macrophage foam cells [26, 27]. However, currently, there are no studies linking GUDCA with the pathophysiology and development of CHD and its subtypes, and this could be a future research direction.

Choline is a precursor of acetylcholine that is essential for lipid metabolism. The main sources of choline were shown to be eggs, milk, fresh vegetables, lean fish, meat, and bread, of which animal food sources were the most important contributors to choline intake [28]. In this study, we found that the level of choline was decreased in the SAP group, compared with the CON group. Studies have shown that plasma choline level in patients with a history of acute myocardial infarction (AMI) was significantly lower than that in patients without a history of AMI [29, 30]. Future studies are needed to explore underlying mechanisms for this observation.

The energy required for normal cardiac function is provided by fatty acid and glucose metabolism. Most ATP is produced by fatty acid (FA) oxidation in cardiomyocytes ([31]). FAs are first catalyzed by acyl-CoA synthetase in the presence of ATP, coenzyme A (COA-SH), and Mg2+ to generate lipoyl CoA, which are then transferred to the mitochondrial matrix for β-oxidation [32]. This study found that FA was increased in patients with SAP. The increase of substrate indicates that the oxidation of FAs could be restricted, resulting in a decrease in ATP production and a lack of energy supply in the ischemic myocardium.

The AMPK pathway is the main regulatory pathway of glycometabolism and lipid metabolism and is believed to play a key role in regulating cellular energy. Its activation is believed to promote the production of ATP and inhibit the consumption of ATP. AMPK can be negatively regulated by ACC and activate PFK2 to promote catabolism, such as glycolysis and fatty acid oxidation [33], and increase energy supply. β-Guandinopropionic acid (GPA) is an endogenous AMPK agonist. In recent years, it has been found that GPA can competitively inhibit creatine kinase from reducing blood pressure in rats with essential hypertension [34]. GPA was found to be safe and well-tolerated in human experiments [35]. Other studies have shown that GPA could reduce the rate of mitochondrial oxygen consumption and increase autophagy flux in the cells of skeletal muscle to mitigate the effects of metabolic diseases [36]. However, few GPA studies have been performed for cardiovascular disease, and their correlation remained unknown. In this study, for the first time, we found a significant difference in serum GPA between patients with SAP and controls. However, further studies using larger cohorts of patients should be performed to validate these observations.

LPC is a metabolite of PC. A large prospective epidemiological study showed that LysoPC (18:1) and LysoPC (18:2) were directly related to the occurrence and development of coronary heart disease [37], and the type of PC was associated with its effect on cardiovascular events [38]. Some studies have shown that S1P had a cardioprotective effect and could protect against ischemic myocardium, which may depend on the activation of RhoA and its downstream protein kinase D. At present, drugs for CHD and ischemia-reperfusion targeting S1P receptor are being developed [39–41]. The decrease in sphingosine 1-phosphate in the SAP group could suggest that the cardioprotective effect of sphingosine 1-phosphate was weakened in these patients.

Despite the promising results observed in this study, some limitations should be highlighted. First, the sample size included in this study was relatively small, and studies with larger clinical sample sizes are needed to confirm our observations further [37, 42]. Second, only patients with SAP were included in the disease group, and the metabolic profiles of
Figure 4: Correlation analysis and clustering heatmap of potential biomarkers in serum. (a) Heatmap of hierarchical clustering analysis of the metabolites determined from serum samples (increasing expression values are coded with blue to red colors. Rows indicate potential biomarkers; columns indicate different groups). (b) Heatmap of correlation analysis of the metabolites determined from serum samples. The rows and columns represent the different metabolites compared in this group. The color blocks at different positions represent the correlation coefficient between the metabolites at corresponding positions. Red represents positive correlation, and blue represents negative correlation; the darker the color, the stronger the correlation. Meanwhile, the significance in correlation was marked with an asterisk.
several other CHD subtypes were not studied or compared. Third, in regard to the metabolomic analyses, we were not able to conduct a comprehensive qualitative and quantitative analysis of all metabolites since we only collected serum samples and did not collect urine and tissue samples. Further, there more unified and rigorous biological sample collection, and processing specification should have been used, and such could have affected the reliability and repeatability of the experimental results, to a certain extent.

5. Conclusion

In this study, we identified 25 potential biomarkers for the clinical diagnosis and treatment of stable angina by comparing and assessing the serum metabolic profiles of patients with SAP. Larger scale, multicenter studies using prospective settings are required to validate these observations.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This study was supported by a multicenter, double-blind, randomized controlled, placebo study of Zhilong Huoxue Tongyu capsule in treating stable angina pectoris of Qi deficiency and blood stasis type (Sichuan Administration of Traditional Chinese Medicine: 2021ZD05).

References

[1] M. Gheorghiade, G. Sopko, L. De Luca et al., “Navigating the crossroads of coronary artery disease and heart failure,” Circulation, vol. 114, no. 11, pp. 1202–1213, 2006.
[2] G. A. Roth, G. A. Mensah, and V. Fuster, “The global burden of cardiovascular diseases and risks: a compass for global action,” Journal of the American College of Cardiology, vol. 76, no. 25, pp. 2980–2981, 2020.
[3] S. S. Virani, A. Alonso, H. J. Aparicio et al., “Heart disease and stroke statistics-2021 update: a report from the American Heart Association,” Circulation, vol. 143, no. 8, pp. e254–e743, 2021.
[4] Q. Shi, H. Zhao, J. Chen et al., “Study on TCM syndrome identification modes of coronary heart disease based on data mining,” Evidence-based Complementary and Alternative Medicine, vol. 2012, Article ID 697028, 2012.
[5] J. T. Brindle, H. Antti, E. Holmes et al., “Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabolomics,” Nature Medicine, vol. 8, no. 12, pp. 1439–1445, 2002.
[6] L. Zhao, L. Wan, X. Qiu, R. Li, S. Liu, and D. Wang, “A metabolomics profiling study on phlegm syndrome and blood-stasis syndrome in coronary heart disease patients using liquid chromatography/quadrupole time-of-flight mass spectrometry,” Evidence-based Complementary and Alternative Medicine, vol. 2014, Article ID 385102, 2014.
[7] A. P. DeFilippis, P. J. Trainor, B. G. Hill et al., “Identification of a plasma metabolomic signature of thrombotic myocardial infarction that is distinct from non-thrombotic myocardial infarction and stable coronary artery disease,” PLoS One, vol. 12, no. 4, article e0175591, 2017.
[8] J. Li, W. Duan, L. Wang, Y. Lu, Z. Shi, and T. Lu, “Metabolomics study revealing the potential risk and predictive value of fragmented QRS for acute myocardial infarction,” Journal of Proteome Research, vol. 19, no. 8, pp. 3386–3395, 2020.
Computational and Mathematical Methods in Medicine

[9] W. Yao, Y. Gao, and Z. Wan, “Serum metabolomics profiling to identify biomarkers for unstable angina,” BioMed Research International, vol. 2017, 2017.

[10] H. Fu, K. Zhu, D. Zhou, Y. Guan, W. Li, and S. Xu, “Identification and validation of plasma metabolomics reveal potential biomarkers for coronary heart disease,” International Heart Journal, vol. 60, no. 6, pp. 1387–1397, 2019.

[11] J. Lu, B. Chen, T. Chen et al., “Comprehensive metabolomics identified lipid peroxidation as a prominent feature in human plasma of patients with coronary heart diseases,” Redox Biology, vol. 12, pp. 899–907, 2017.

[12] N. P. Paynter, R. Balasubramanian, F. Giuliani et al., “Metabolic predictors of incident coronary heart disease in women,” Circulation, vol. 137, no. 8, pp. 841–853, 2018.

[13] I. Nemet, P. P. Saha, N. Gupta et al., “A cardiovascular-disease-linked gut microbial metabolite acts via adrenergic receptors,” Cell, vol. 180, no. 5, article e22, pp. 862–877.e22, 2020.

[14] M. Huang, H. Zhao, S. Gao et al., “Identification of coronary heart disease biomarkers with different severities of coronary stenosis in human urine using non-targeted metabolomics based on UPLC-Q-TOF/MS,” Clinica Chimica Acta, vol. 497, pp. 95–103, 2019.

[15] S. E. Stein and D. R. Scott, “Optimization and testing of mass spectral library search algorithms for compound identification,” Journal of the American Society for Mass Spectrometry, vol. 5, no. 9, pp. 859–866, 1994.

[16] G. Maheshwari, R. Ringsgeis, G. Wen et al., “Branch-chained fatty acids as mediators of the activation of hepatic peroxisome proliferator-activated receptor alpha by a fungal lipid extract,” Biomolecules, vol. 10, no. 9, pp. 1259, 2020.

[17] M. Rakhshandehroo, B. Knoch, M. Müller, and S. Kersten, “Peroxisome proliferator-activated receptor alpha target genes,” PPAR Research, vol. 2010, Article ID 612089, 2010.

[18] J. Frosen, J. Cebreal, A. M. Robertson, and T. Aoki, “Flow-induced, inflammation-mediated arterial wall remodeling in the formation and progression of intracranial aneurysms,” Neurosurgical Focus, vol. 47, no. 1, p. E21, 2021.

[19] V. Hadi, N. Pahlavani, M. Malekahmadi et al., “Nigella sativa in controlling type 2 diabetes, cardiovascular, and rheumatoid arthritis diseases: molecular aspects,” Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences, vol. 26, p. 20, 2021.

[20] S. Y. Liu, C. C. Huang, S. F. Huang et al., “Pioglitazone ameliorates acute endotoxemia-induced acute on chronic renal dysfunction in cirrhotic ascitic rats,” Cell, vol. 10, no. 11, 2021.

[21] D. Zapolska-Downar and M. Naruszewicz, “Propionate reduces the cytokine-induced VCAM-1 and ICAM-1 expression by inhibiting nuclear factor-kappa B (NF-kappaB) activation,” Journal of Physiology and Pharmacology, vol. 60, no. 2, pp. 123–131, 2009.

[22] S. S. Soskic, B. D. Dobutovic, E. M. Sudar et al., “Peroxisome proliferator-activated receptors and atherosclerosis,” Angiology, vol. 62, no. 7, pp. 523–534, 2011.

[23] R. M. Bidanchi, L. Lalrindika, M. Khushboo et al., “Antioxidative activity of allicic acid against lead acetate induced testicular and hepato-renal oxidative damages and pathophysiological changes in male long Evans rats,” Environmental Pollution, vol. 302, article 119048, 2022.

[24] J. L. Cordeiro, J. D. Neves, F. Nicola et al., “Arundic acid (ONO-2506) attenuates neuroinflammation and prevents motor impair-

[25] Y. Tang, J. Liu, Y. Wang et al., “PARP14 inhibits microglial activation via LPAR5 to promote post-stroke functional recovery,” Autophagy, vol. 17, no. 10, pp. 2905–2922, 2021.

[26] F. Huang, C. M. Pariente, and A. Borsini, “From dried bear bile to molecular investigation: a systematic review of the effect of bile acids on cell apoptosis, oxidative stress and inflammation in the brain, across pre-clinical models of neurological, neurodegenerative and neuropsychiatric disorders,” Brain, Behavior, and Immunity, vol. 99, pp. 132–146, 2022.

[27] K. Huang, C. Liu, M. Peng et al., “Glycoursodeoxycholic acid ameliorates atherosclerosis and alters gut microbiota in apolipoprotein E-deficient mice,” Journal of the American Heart Association, vol. 10, no. 7, article e019820, 2021.

[28] A. Van Parys, T. Karlsson, K. J. Vinknes et al., “Food sources contributing to intake of choline and individual choline forms in a Norwegian cohort of patients with stable angina pectoris,” Frontiers in Nutrition, vol. 8, article 676026, 2021.

[29] J. Guo, P. Hang, Y. Jie et al., “The association between RGS4 and choline in cardiac fibrosis,” Cell Communication and Signaling, vol. 19, no. 1, p. 46, 2021.

[30] D. M. Mueller, M. Allenspach, A. Othman et al., “Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control,” Atherosclerosis, vol. 243, no. 2, pp. 638–644, 2015.

[31] S. C. Kolwicz Jr., S. Purohit, and R. Tian, “Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes,” Circulation Research, vol. 113, no. 5, pp. 603–616, 2013.

[32] S. Jitrapakdee and J. C. Wallace, “The biotin enzyme family: conserved structural motifs and domain rearrangements,” Current Protein & Peptide Science, vol. 4, no. 3, pp. 217–229, 2003.

[33] I. Oudman, J. F. Clark, and L. M. Brewster, “The effect of the creatine analogue beta-guanidinopropionic acid on energy metabolism: a systematic review,” PLoS One, vol. 8, no. 1, article e52879, 2013.

[34] L. M. Brewster, “Paradoxical increase in body mass induced by Beta-guanidinopropionic acid in juvenile spontaneously hypertensive rats,” Cereus, vol. 13, no. 11, article e19394, 2021.

[35] F. A. Karamat, D. L. Horjus, Y. C. Haan et al., “The acute effect of beta-guanidinopropionic acid versus creatine or placebo in healthy men (ABC-trial): a randomized controlled first-in-human trial,” British Journal of Clinical Pharmacology, vol. 83, no. 12, pp. 2626–2635, 2017.

[36] C. L. Crocker, B. L. Baumgarner, and S. T. Kinsey, “Beta-Guanidinopropionic acid and metformin differentially impact autophagy, mitochondria and cellular morphology in developing C2C12 muscle cells,” Journal of Muscle Research and Cell Motility, vol. 41, no. 2-3, pp. 221–237, 2020.

[37] P. Wurtz, A. S. Havulmina, P. Soininen et al., “Metabolite profiling and cardiovascular event risk,” Circulation, vol. 131, no. 9, pp. 774–785, 2015.

[38] P. J. Yeon, S.-H. Lee, M.-J. Shin, and G.-S. Hwang, “Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction,” PLoS One, vol. 10, no. 8, 2015.

[39] B. S. Yong, C. S. Brand, S. Y. Xiang et al., “Selective coupling of the S1P3 receptor subtype to S1P-mediated RhoA activation and cardioprotection,” Journal of Molecular and Cellular Cardiology, vol. 103, pp. 1–10, 2017.
[40] V. H. Brait, G. Tarrason, A. Gavalda, N. Godessart, and A. M. Planas, “Selective sphingosine 1-phosphate receptor 1 agonist is protective against ischemia/reperfusion in mice,” Stroke, vol. 47, no. 12, pp. 3053–3056, 2016.

[41] K. Sugahara, Y. Maeda, K. Shimano et al., “Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk,” British Journal of Pharmacology, vol. 174, no. 1, pp. 15–27, 2017.

[42] L. Zhang, T.-T. Wei, Y. Li et al., “Functional metabolomics characterizes a key role for N-Acetylneuraminic acid in coronary artery diseases,” Circulation, vol. 137, no. 13, p. 1374, 2018.